产品名称 |
U-138MG人神经星形胶质母细胞瘤 |
货号 |
ZQ0927 |
产品介绍 |
U-138MG人神经星形胶质母细胞瘤是 J. Ponten 及其同事于 1966 年至 1969 年从恶性神经胶质瘤衍生的许多细胞系之一(另见ATCC HTB-14和ATCC HTB-15)。它在形态上与ATCC HTB-14不同,并且增殖速度较慢。到 1974 年 3 月观察到支原体污染并治愈。注:据报道,来自不同个体的两种胶质母细胞瘤细胞系 U-118 MG (HTB-15) 和 U-138 MG (HTB-16) 具有相同的 VNTR 和相似的 STR 模式。U-118 MG 和 U-138 MG 在细胞遗传学上非常相似,并且共享至少六个衍生标记染色体。 |
种属 |
人 |
性别/年龄 |
男/47岁 |
组织 |
脑 |
疾病 |
胶质母细胞瘤;Ⅳ级 |
细胞类型 |
肿瘤细胞 |
形态学 |
多边形的 |
生长方式 |
贴壁 |
倍增时间 |
47 hours (PubMed=9842975); ~70 hours (DSMZ=ACC-291) |
培养基和添加剂 |
DMEM (中乔新舟 货号:ZQ-100)+10%胎牛血清(中乔新舟 货号:ZQ500-A)+1%P/S(中乔新舟 货号:CSP006) |
推荐完全培养基货号 |
|
生物安全等级 |
BSL-1 |
培养条件 |
95%空气,5%二氧化碳;37℃ |
STR位点信息 |
Amelogenin: X,Y
CSF1PO: 12
|
抗原表达/受体表达 |
*** |
基因表达 |
*** |
保藏机构 |
ATCC; HTB-16;BCRJ; 0239;DSMZ; ACC-291 |
供应限制 |
仅供科研使用 |
货号 |
ZQ0927 |
发货规格 |
活细胞:T25培养瓶*1瓶或者1ml 冻存管*1支(细胞量约为5 x 10^5 cells/vial)二选一 |
发货形式 |
活细胞:常温运输;冻存管:干冰运输 |
储存温度 |
活细胞:培养箱;冻存管:液氮罐 |
产地 |
中国 |
供应限制 |
仅供科研使用 |
PubMed=4313504; DOI=10.1111/j.1699-0463.1968.tb03502.x
Ponten J., Macintyre E.H.
Long term culture of normal and neoplastic human glia.
Acta Pathol. Microbiol. Scand. 74:465-486(1968)
PubMed=4337530; DOI=10.1111/j.1699-0463.1972.tb02176.x
Macintyre E.H., Ponten J., Vatter A.E.
The ultrastructure of human and murine astrocytes and of human fibroblasts in culture.
Acta Pathol. Microbiol. Scand. A. 80:267-283(1972)
PubMed=4134536; DOI=10.1002/ijc.2910120215
Westermark B.
The deficient density-dependent growth control of human malignant glioma cells and virus-transformed glia-like cells in culture.
Int. J. Cancer 12:438-451(1973)
PubMed=4369403; DOI=10.1002/1097-0142(197408)34:2<274::AID-CNCR2820340209>3.0.CO;2-4
Wahlstrom T., Linder E., Saksela E., Westermark B.
Tumor-specific membrane antigens in established cell lines from gliomas.
Cancer 34:274-279(1974)
DOI=10.1007/978-1-4757-1647-4_7
Ponten J.
Neoplastic human glia cells in culture.
(In) Human tumor cells in vitro; Fogh J. (eds.); pp.175-206; Springer; New York (1975)
PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)
PubMed=450131; DOI=10.1038/279797a0
Day R.S. III, Ziolkowski C.H.J.
Human brain tumour cell strains with deficient host-cell reactivation of N-methyl-N'-nitro-N-nitrosoguanidine-damaged adenovirus 5.
Nature 279:797-799(1979)
PubMed=22282976; DOI=10.1093/carcin/1.1.21
Day R.S. III, Ziolkowski C.H.J., Scudiero D.A., Meyer S.A., Mattern M.R.
Human tumor cell strains defective in the repair of alkylation damage.
Carcinogenesis 1:21-32(1980)
PubMed=6260907; DOI=10.1097/00005072-198105000-00001
Bigner D.D., Bigner S.H., Ponten J., Westermark B., Mahaley M.S. Jr., Ruoslahti E., Herschman H., Eng L.F., Wikstrand C.J.
Heterogeneity of genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas.
J. Neuropathol. Exp. Neurol. 40:201-229(1981)
PubMed=6220172
Dracopoli N.C., Fogh J.
Polymorphic enzyme analysis of cultured human tumor cell lines.
J. Natl. Cancer Inst. 70:469-476(1983)
PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)
PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)
PubMed=3675803
Bigner S.H., Bjerkvig R., Laerum O.D., Muhlbaier L.H., Bigner D.D.
DNA content and chromosomes in permanent cultured cell lines derived from malignant human gliomas.
Anal. Quant. Cytol. Histol. 9:435-444(1987)
PubMed=2454731
Nister M., Libermann T.A., Betsholtz C., Pettersson M., Claesson-Welsh L., Heldin C.-H., Schlessinger J., Westermark B.
Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines.
Cancer Res. 48:3910-3918(1988)
DOI=10.1016/B978-0-12-333530-2.50005-8
Nister M., Westermark B.
Human glioma cell lines.
(In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.17-42; Academic Press; New York (1994)
PubMed=9842975; DOI=10.1002/(SICI)1097-0215(19981218)79:6<640::AID-IJC15>3.0.CO;2-z
Weller M., Rieger J., Grimmel C., Van Meir E.G., De Tribolet N., Krajewski S., Reed J.C., von Deimling A., Dichgans J.
Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses.
Int. J. Cancer 79:640-644(1998)
PubMed=10416987; DOI=10.1111/j.1750-3639.1999.tb00536.x
Ishii N., Maier D., Merlo A., Tada M., Sawamura Y., Diserens A.-C., Van Meir E.G.
Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines.
Brain Pathol. 9:469-479(1999)
PubMed=14614447; DOI=10.1038/sj.onc.1207198
Wischhusen J., Naumann U., Ohgaki H., Rastinejad F., Weller M.
CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death.
Oncogene 22:8233-8245(2003)
PubMed=14655754; DOI=10.1111/j.1750-3639.2003.tb00479.x
Bahr O., Rieger J., Duffner F., Meyermann R., Weller M., Wick W.
P-glycoprotein and multidrug resistance-associated protein mediate specific patterns of multidrug resistance in malignant glioma cell lines, but not in primary glioma cells.
Brain Pathol. 13:482-494(2003)
PubMed=14961077; DOI=10.1038/sj.onc.1207244
Wang Y.-L., Zhu S.-J., Cloughesy T.F., Liau L.M., Mischel P.S.
p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition.
Oncogene 23:1283-1290(2004)
PubMed=16697959; DOI=10.1016/j.ccr.2006.03.030
Lee J., Kotliarova S., Kotliarov Y., Li A.-G., Su Q., Donin N.M., Pastorino S., Purow B.W., Christopher N., Zhang W., Park J.K., Fine H.A.
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines.
Cancer Cell 9:391-403(2006)
PubMed=17595512; DOI=10.1159/000104150
Rieger J., Frank B., Weller M., Wick W.
Mechanisms of resistance of human glioma cells to Apo2 ligand/TNF-related apoptosis-inducing ligand.
Cell. Physiol. Biochem. 20:23-34(2007)
PubMed=19365568; DOI=10.1371/journal.pone.0005209
Bax D.A., Little S.E., Gaspar N., Perryman L., Marshall L., Viana-Pereira M., Jones T.A., Williams R.D., Grigoriadis A., Vassal G., Workman P., Sheer D., Reis R.M., Pearson A.D.J., Hargrave D., Jones C.
Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development.
PLoS ONE 4:E5209-E5209(2009)
PubMed=19435942; DOI=10.1215/15228517-2009-025
Ichimura K., Pearson D.M., Kocialkowski S., Backlund L.M., Chan R., Jones D.T.W., Collins V.P.
IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.
Neuro-oncol. 11:341-347(2009)
PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)
PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)
PubMed=22570425; DOI=10.1093/neuonc/nos072
Bady P., Diserens A.-C., Castella V., Kalt S., Heinimann K., Hamou M.-F., Delorenzi M., Hegi M.E.
DNA fingerprinting of glioma cell lines and considerations on similarity measurements.
Neuro-oncol. 14:701-711(2012)
PubMed=27582061; DOI=10.1126/scitranslmed.aaf6853
Allen M., Bjerke M., Edlund H., Nelander S., Westermark B.
Origin of the U87MG glioma cell line: good news and bad news.
Sci. Transl. Med. 8:354re3.1-354re3.4(2016)
PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)
PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)
PubMed=33385022; DOI=10.1016/j.dib.2020.106643
de Sousa J.F., da Silva P., Serafim R.B., Nociti R.P., Moreira C.G., Silva W.A., Valente V.
RNA sequencing data of different grade astrocytoma cell lines.
Data Brief 34:106643.1-106643.13(2021)